FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment for BRAFV600E-Mutant Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study
J. Clin. Oncol 2023 Jun 23;[EPub Ahead of Print], S Stintzing, K Heinrich, D Tougeron, DP Modest, I Schwaner, J Eucker, R Pihusch, M Stauch, F Kaiser, C Kahl, M Karthaus, C Müller, C Burkart, A Reinacher-Schick, S Kasper-Virchow, L Fischer von Weikersthal, B Krammer-Steiner, GW Prager, J Taieb, V HeinemannFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.